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CASE DESCRIPTION
We present the case of a 46-year-old man with a history of class III morbid obesity, ulcerative proctocolitis, and prediabetes who underwent ESG for management of his obesity (Video 1; available online at www.VideoGIE.org). His pre-ESG weight was 298 pounds, with a body mass index of 42.8 kg/m 2 . The ESG was performed uneventfully. However, owing to dietary indiscretion 6 days after the procedure, he experienced a leak complicated by symptomatic perigastric abscess and left pleural effusion. CT evaluation with oral contrast material and an upper-GI series with gastrograffin did not demonstrate extravasation of the contrast material. Because of his progressive symptoms, the perigastric abscess was assessed with EUS ( Figs. 1 and 2 ) and successfully internally drained by use of a wire-guided 10F double-pigtail plastic stent through a transgastric approach (Fig. 3) . Follow-up imaging demonstrated complete resolution of the abscess, and the stent was subsequently removed (Fig. 4) .
The patient is currently doing well 6 months after ESG and 5 months after successful drainage of the perigastric abscess. He has had a weight loss of 38 pounds (12.7% total body weight loss), and his current body mass index is 36 kg/m 2 .
CONCLUSION
Post-ESG abscess occurs in less than 2% to 3% of published ESG cases and frequently follows dietary indiscretion within the first 2 weeks after the procedure. Endoscopic transgastric drainage is an effective, minimally invasive option for the management of post-ESG abscess.
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